Swedish Boost For Life Sciences Innovation Resonates Around Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Sweden’s government has allocated 4 billion kroner for the R&D sector and SEK 600 million specifically for life science in the hopes of rejuvenating Swedish R&D and getting the nation back on the top rankings of medicine innovation. It’s a theme being heard in other European countries.
You may also be interested in...
National Strategy For Biomedical Innovation Simmering On Hamburg’s Agenda
FDA commissioner says all stakeholders need to come to the table to develop a path for maintaining U.S. preeminence in making medical discoveries and moving them through the pharmaceutical pipeline into patients’ hands.
Sweden’s Reference Pricing Proposal: A Five-Year Doomsday Clock For Innovation?
Sweden may link its existing value-based pricing system with international reference pricing to cut drug expenditure, a move the pharmaceuticals industry says would devastate domestic R&D there.
German Joy For Pharma As Drug Discount Prices Stay Hidden
The updated German Pharmaceutical Act will ensure that drug prices negotiated there between pharmaceutical manufacturers and health insurers will remain hidden from public view, as Germany’s government seeks to avoid a pan-European drug price crash.